| Dr Mandeep Dhami, MD | |
|
330 Washington St Ste 220, Norwich, CT 06360-2700 | |
| (860) 886-8362 | |
| (860) 886-9262 |
| Full Name | Dr Mandeep Dhami |
|---|---|
| Gender | Male |
| Speciality | Hematology |
| Experience | 42 Years |
| Location | 330 Washington St Ste 220, Norwich, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639154628 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD2018-0616 (New Mexico) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 29948 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Day Kimball Hospital | Putnam, CT | Hospital |
| William W Backus Hospital | Norwich, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eastern Connecticut Hematology And Oncology Associates Pc | 3870552094 | 8 |
News Archive
A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
The impact on lung cells of Heat not Burn products-a hybrid between traditional cigarettes and electronic vaping devices-may be no less harmful than that of conventional cigarettes, suggest the findings of a small comparative study, published online in the journal Thorax.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has received a Ringier Technology Innovation Award for its role in helping Chinese laboratories quickly develop melamine detection capabilities following the discovery of melamine-tainted milk and infant formula in China. The award was presented by Ringier Trade Publishing, which publishes China's leading food industry magazine, Food Manufacturing Journal.
› Verified 9 days ago
| Entity Name | Eastern Connecticut Hematology & Oncology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972604338 PECOS PAC ID: 3870552094 Enrollment ID: O20041005000138 |
News Archive
A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
The impact on lung cells of Heat not Burn products-a hybrid between traditional cigarettes and electronic vaping devices-may be no less harmful than that of conventional cigarettes, suggest the findings of a small comparative study, published online in the journal Thorax.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has received a Ringier Technology Innovation Award for its role in helping Chinese laboratories quickly develop melamine detection capabilities following the discovery of melamine-tainted milk and infant formula in China. The award was presented by Ringier Trade Publishing, which publishes China's leading food industry magazine, Food Manufacturing Journal.
› Verified 9 days ago
| Entity Name | Day Kimball Healthcare, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649243478 PECOS PAC ID: 5092773549 Enrollment ID: O20041229001007 |
News Archive
A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
The impact on lung cells of Heat not Burn products-a hybrid between traditional cigarettes and electronic vaping devices-may be no less harmful than that of conventional cigarettes, suggest the findings of a small comparative study, published online in the journal Thorax.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has received a Ringier Technology Innovation Award for its role in helping Chinese laboratories quickly develop melamine detection capabilities following the discovery of melamine-tainted milk and infant formula in China. The award was presented by Ringier Trade Publishing, which publishes China's leading food industry magazine, Food Manufacturing Journal.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mandeep Dhami, MD 330 Washington St Ste 220, Norwich, CT 06360-2700 Ph: (860) 912-2147 | Dr Mandeep Dhami, MD 330 Washington St Ste 220, Norwich, CT 06360-2700 Ph: (860) 886-8362 |
News Archive
A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
The impact on lung cells of Heat not Burn products-a hybrid between traditional cigarettes and electronic vaping devices-may be no less harmful than that of conventional cigarettes, suggest the findings of a small comparative study, published online in the journal Thorax.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has received a Ringier Technology Innovation Award for its role in helping Chinese laboratories quickly develop melamine detection capabilities following the discovery of melamine-tainted milk and infant formula in China. The award was presented by Ringier Trade Publishing, which publishes China's leading food industry magazine, Food Manufacturing Journal.
› Verified 9 days ago
Dr. Ting Li, M.D., PH.D., F.A.C.C Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 112 Lafayette St, Norwich, CT 06360 Phone: 860-572-5400 Fax: 860-245-0001 | |
Ankit Gupta, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 330 Washington St Ste 430, Norwich, CT 06360 Phone: 860-886-1862 Fax: 860-886-2046 | |
Dr. Mohammed A Qureshi, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 326 Washington St, Norwich, CT 06360 Phone: 860-889-8331 | |
Kandhasamy Jagathambal, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 330 Washington St, Ste 220 Eastern Ct Hematology & Oncology, Norwich, CT 06360 Phone: 860-886-8362 Fax: 860-886-9262 | |
Dr. Paras Satish Bhatt, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 164 Ontrobando Ave, Norwich, CT 06360 Phone: 860-889-9180 | |
Maria Sabsay Goral, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 326 Washington St, The William W.backus Hospital, Norwich, CT 06360 Phone: 860-885-6420 Fax: 860-892-6984 | |
Joselito Endaya, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Towne Park Plz, Norwich, CT 06360 Phone: 860-887-0010 Fax: 860-887-0178 |